Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

PENNSYLVANIA PACE's HALCION PROSPECTIVE DUR HAS CUT CLAIMS BY 95% in the first two months of operation. The prospective drug utilization review program specifically instructs pharmacies that reimbursement is prohibited if prescriptions exceed the dosage or treatment duration specified in Upjohn's labeling. In 1991, the program averaged about 5,500 claims monthly for the benzodiazepine. In February and March of this year, claims fell below 300. Pennsylvania's Pharmaceutical Assistance Contract for the Elderly provides outpatient drug coverage for low-income elderly who do not qualify for Medicaid. Halcion (triazolam) was chosen as the first product for the ProDUR program in part because of the publicity surrounding the product's withdrawal by British authorities in October. PACE is planning to expand ProDUR to the entire benzodiazepine/hypnotic class once manufacturers comply with FDA's request to relabel the products to emphasize short-term therapy ("The Pink Sheet" Dec. 16, 1991, T&G-1). The ProDUR program permits no pharmacy override of the prescription limits but does allow physicians to appeal the restrictions on a case-by-case basis. PACE has received about 500 appeal letters and approved about 25, with all of the approvals provided to patients with terminal cancer, state officials said. The program is also putting together a ProDUR advisory board to consist of five physicians, five pharmacists, a social worker and a PACE enrollee. PACE plans to expand ProDUR to include all H[2]-receptor antagonists and nonsteroidal anti- inflammatory drugs beginning July 1. While PACE officials said ProDUR is a quality of care rather than cost-containment initiative, they estimate that one-year savings on the high-volume H[2] and NSAID products could reach $18 mil. as a result of coupling drug utilization review with payment denials. PACE has been considering payment limits for H[2] products for some time, after finding evidence of mismedication and long-term use of acute doses ("The Pink Sheet" Sept. 16, 1991, p. 15).

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts